Laleh Jalilian1, Emma Essock-Burns2, Yan Li1, Soonmee Cha1,3, Susan Chang3, Michael Prados3, Nicholas Butowski3, Sarah J. Nelson1,2
1Radiology & Biomedical Imaging, UCSF, San Francisco, CA, USA; 2Bioengineering, UCSF, San Francisco, CA, USA; 3Neurological Surgery, UCSF, San Francisco, CA, USA
Despite advances in treatment modalities, patients with glioblastoma multiforme have an overall survival of 15 months. Anti-angiogenic therapies administered with temozolomide have been reported to cause restriction on diffusion-weighted imaging (DWI), which may serve as an adjunct to the assessment of therapy response. In this study, 100 newly diagnosed GBM patient were administered either a) temozolomide alone, b) temozolomide and a protein kinase C inhibitor, or c) temozolomide and a VEGF antibody. The results demonstrate that imaging biomarkers used to predict response and prognosis to therapy need to be tailored to take into account the specific treatment regimen being considered.